BMY has been having a good run for the past three months. The stock recently touched a 52-week high. We believe there is more ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

Speaking of the pipeline, Bristol-Myers Squibb has 55 compounds in development. In particular, Cobenfy, a novel treatment for adults with the psychiatric disorder schizophrenia, just received FDA ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...